Related and Nonrelated Parties [Axis]
Nonrelated Party [Member]
Related Party [Member]
Equity Components [Axis]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Antidilutive Securities [Axis]
Share-Based Payment Arrangement, Option [Member]
Unvested Restricted Stock [Member]
Product and Service [Axis]
Soft Tissue Repair Products [Member]
Bone Fusion Products [Member]
Statistical Measurement [Axis]
Minimum [Member]
Maximum [Member]
Business Combination [Axis]
CarePICS Acquisition [Member]
Long-Term Debt, Type [Axis]
CRG Term Loan [Member]
Long-Lived Asset, Class [Axis]
Furniture and Fixtures [Member]
Office Equipment [Member]
Leasehold Improvements [Member]
Computer Equipment [Member]
Intangible Asset, Finite-Lived, Class [Axis]
Intangible Assets [Member]
Developed Technology [Member]
Software, Internally Developed [Member]
Class of Stock [Axis]
Class A Preferred Shares [Member]
Legal Entity [Axis]
Pixalere Healthcare Inc. [Member]
Investment, Name [Axis]
Pixalere Healthcare USA LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Precision Healing Merger Agreement [Member]
Accredited Investors [Member]
Warrant [Member]
Warrant One [Member]
Disposal Group Name [Axis]
Tissue Health Plus [Member]
Asset Acquisition [Axis]
Unit Purchase Agreement [Member]
Patents [Member]
Customer Relationships and Other [Member]
Licensing Agreements [Member]
Amortizable Intangible Assets [Member]
BMI License Agreement [Member]
Common Units [Member]
ChemoMouthpiece, LLC [Member]
Investor [Member]
Direct Dermatology Inc. [Member]
Series B-2 Preferred Shares [Member]
Biomimetic Innovations Limited [Member]
SI Healthcare Technologies LLC [Member]
Office Space One [Member]
Office Space Two [Member]
CRG Term Loan Agreement [Member]
Debt Instrument [Axis]
Backend Fee [Member]
Paid In Kind Interest [Member]
BIAKOS License Agreement [Member]
Rochal Industries LLC [Member]
BIAKOS Agreement [Member]
ABF License Agreement [Member]
Product and Service, Other [Member]
Debrider License Agreement [Member]
Applied Asset Purchase Agreement [Member]
Business Combination, Contingent Consideration, Type [Axis]
Cash Closing Consideration [Member]
Stock Closing Consideration [Member]
Services Agreement [Member]
License Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others, Type [Axis]
Royalty Agreement Terms [Member]
Plan Name [Axis]
2024 Omnibus Long-Term Incentive Plan [Member]
2014 Omnibus Long Term Incentive Plan [Member]
Award Type [Axis]
Restricted Stock [Member]
Consulting Agreement [Member]
Ms Salamone [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Entity Listing, Par Value Per Share
Defined Benefit Plan [Table]
Defined Benefit Plan Disclosure [Line Items]
Assets
Current assets
Cash
Accounts receivable, net
Inventory, net
Prepaid and other assets
Current assets related to discontinued operations (Note 3)
Total current assets
Long-term assets
Intangible assets, net
Goodwill
Investment in equity securities
Right of use assets – operating leases
Property and equipment, net
Total long-term assets
Total assets
Liabilities and shareholders’ equity
Current liabilities
Accounts payable
Accrued bonuses and commissions
Accrued royalties and expenses
Earnout liabilities – current
Operating lease liabilities – current
Current liabilities related to discontinued operations (Note 3)
Total current liabilities
Long-term liabilities
Long-term debt
Operating lease liabilities – long-term
Other long-term liabilities
Total long-term liabilities
Total liabilities
Commitments and contingencies (Note 9)
Shareholders’ equity
Common Stock: $0.001 par value, 20,000,000 shares authorized; 9,165,148 issued and outstanding as of March 31, 2026 and 8,946,913 issued and outstanding as of December 31, 2025
Additional paid-in capital
Accumulated deficit
Total Sanara MedTech shareholders’ equity
Equity attributable to noncontrolling interest
Total shareholders’ equity
Total liabilities and shareholders’ equity
Statement of Financial Position [Abstract]
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Net Revenue
Cost of goods sold
Gross profit
Operating expenses
Selling, general and administrative
Research and development
Depreciation and amortization
Total operating expenses
Operating income
Other income (expense)
Interest expense
Share of losses from equity method investments
Interest income
Gain on disposal of property and equipment
Total other income (expense)
Net income (loss) from continuing operations
Net income (loss) from discontinued operations (Note 3)
Net income (loss)
Less: Net loss attributable to noncontrolling interest from continuing operations
Net income (loss) attributable to Sanara MedTech shareholders
Net income (loss) per share, basic:
Continuing operations
Discontinued operations
Net income (loss) per share of common stock, basic
Net income (loss) per share, diluted:
Continuing operations
Discontinued operations
Net income (loss) per share of common stock, diluted
Weighted average number of common shares outstanding, basic
Weighted average number of common shares outstanding, diluted
Statement [Table]
Statement [Line Items]
Balance
Balance, shares
Share-based compensation
Share-based compensation, shares
Change in noncontrolling interest
Net income (loss)
Net settlement and retirement of equity-based awards
Net settlement and retirement of equity-based awards, shares
Balance
Balance, shares
Statement of Cash Flows [Abstract]
Cash flows from operating activities:
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization
Gain on disposal of property and equipment
Credit loss expense
Inventory obsolescence
Share-based compensation
Noncash lease expense
Share of losses from equity method investments
Back-end fee
Paid-in-kind interest
Accretion of finance liabilities
Amortization and write-off of debt issuance costs
Changes in operating assets and liabilities:
Accounts receivable, net
Accounts receivable – related parties
Inventory, net
Prepaid and other assets
Accounts payable
Accounts payable – related parties
Accrued royalties and expenses
Accrued bonuses and commissions
Operating lease liabilities
Net cash used in operating activities
Cash flows from investing activities:
Purchases of property and equipment
Proceeds from disposal of property and equipment
Investment in equity securities
Net cash used in investing activities
Cash flows from financing activities:
Loan proceeds, net of debt issuance costs of zero in 2026 and $183,750 in 2025
Net settlement of equity-based awards
Cash payment of finance and earnout liabilities
Net cash provided by (used in) financing activities
Net increase (decrease) in cash
Cash, beginning of period
Cash, end of period
Cash paid during the period for:
Interest
Taxes
Supplemental noncash investing and financing activities:
Non-monetary exchange to acquire intangible assets
Conversion of note receivable into equity method investment
Net of debt issuance costs
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Insider Trading Arrangements [Line Items]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b51 Arr Trmntd Flag
Non Rule 10b51 Arr Trmntd Flag
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
Rule 10b5-1 Arrangement Modified
Non-Rule 10b5-1 Arrangement Modified
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF BUSINESS AND BACKGROUND
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]
CAREPICS ACQUISITION
Intangible Asset, Goodwill and Other [Abstract]
GOODWILL AND INTANGIBLES, NET
Schedule of Investments [Abstract]
INVESTMENTS IN EQUITY SECURITIES
Operating Leases
OPERATING LEASES
Debt Disclosure [Abstract]
DEBT AND CREDIT FACILITIES
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES
Equity [Abstract]
SHAREHOLDERS’ EQUITY
Related Party Transactions [Abstract]
RELATED PARTIES
Segment Reporting [Abstract]
SEGMENT REPORTING
Principles of Consolidation and Basis of Presentation
Reclassifications
Discontinued Operations
Use of Estimates
Cash and Cash Equivalents
Income/Loss Per Share
Revenue Recognition
Accounts Receivable Allowances
Inventories
Property and Equipment
Internal Use Software
Goodwill
Intangible Assets
Impairment of Long-Lived Assets
Investments in Equity Securities
Fair Value Measurement
Financial Instruments Not Measured at Fair Value
Income Taxes
Share-based Compensation
Research and Development Costs
Recently Issued Accounting Pronouncements
SCHEDULE OF NUMERATOR AND DENOMINATOR OF BASIC AND DILUTED NET INCOME (LOSS) PER SHARE
SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE
SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES
SCHEDULE OF PROPERTY AND EQUIPMENT
SCHEDULE OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION
SCHEDULE OF DISCONTINUED OPERATIONS
Business Combination [Table]
Business Combination [Line Items]
SCHEDULE OF TOTAL PURCHASE CONSIDERATION
SCHEDULE OF ACQUIRED ASSETS AND LIABILITIES
SCHEDULE OF CHANGES IN CARRYING AMOUNT OF GOODWILL
SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS
SCHEDULE OF FUTURE AMORTIZATION EXPENSE
SCHEDULE OF INVESTMENTS
SCHEDULE OF LOSS FROM EQUITY METHOD INVESTMENT
SCHEDULE OF OPERATING LEASE LIABILITY
SCHEDULE OF LONG-TERM DEBT
SCHEDULE OF MATURITIES OUTSTANDING
SUMMARY OF RESTRICTED STOCK ACTIVITY
SCHEDULE OF STOCK OPTION ACTIVITY
SCHEDULE OF OPERATIONS, ASSETS AND CAPITAL EXPENDITURES FOR OUR BUSINESS SEGMENTS
SCHEDULE OF RECONCILIATION OF NET INCOME (LOSS) FROM CONTINUING OPERATIONS TO ADJUSTED EBITDA
Number of operating segments
Number of reportable segments
Net income (loss) from discontinued operations
Less: Net loss attributable to noncontrolling interests from continuing operations
Weighted average shares, basic
Dilutive effect of stock options
Dilutive effect of unvested shares
Weighted average shares, diluted
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities
Nature of Operation, Product Information, Concentration of Risk [Table]
Product Information [Line Items]
Total Net Revenue
Property, Plant, and Equipment [Table]
Property, Plant, and Equipment [Line Items]
Property and equipment, gross
Useful Life
Less accumulated depreciation
Property and equipment, net
Balance at December 31, 2025
Revaluation of earnout liabilities
Balance at March 31, 2026
Revenues
Accounts receivable
Bad debt expense
Allowance for credit losses
Allowance for customer rebates and deductions
Inventory obsolescence expense
Allowance for obsolete and slow-moving inventory
Estimated useful lives
Depreciation
Internal use software capitalized costs
Impairment of goodwill
Impairment of long lived assets
Number of investments
Contingent consideration liability
Acquisition contingent liability
Contingent liability
Estimated fair value of the long-term debt
Net of debt issuance costs
DiscontinuedOperationsTable [Table]
Asset impairment charges recognized
Intangible asset impairment charges
Asset impairment charges
Investments
Purchase of additional shares
Conversion rate
Ownership interest
Ownership value
Cash consideration
Issuance of shares
Payment in cash
Share price
Options to acquire shares
Weighted exercise price
Warrants to purchase shares
Exercise price
Expiration date
Options remaining to be exercised
Carrying value of the technology
Disposal Groups, Including Discontinued Operations [Table]
Disposal Group, Including Discontinued Operations [Line Items]
Current assets
Accounts receivable, net
Prepaids
Current assets related to discontinued operations
Current liabilities
Accrued bonuses and commissions
Accrued royalties and expenses
Current liabilities related to discontinued operations
Net revenue
Operating expenses
Selling, general, and administrative expenses
Research and development
Depreciation and amortization
Total operating expenses
Operating loss
Other income (expense)
Other income
Loss on disposal of property and equipment
Total other income (expense)
Net income (loss) from discontinued operations
Operating Activities:
Loss on disposal of property and equipment
Prepaid and other assets
Depreciation
Cash consideration
Contingent consideration
Direct transaction costs
Total purchase consideration
Developed technology
Debt assumed
Net assets acquired
Asset Acquisition [Table]
Asset Acquisition [Line Items]
Cash consideration for asset acquisition
Long-term debt assumed in business combination
Earnout payment description
Earnout payable in cash percentage
Earnout payable in Purchaser's election percentage
Earnout payable
Earnout payable price per patient
Balance as of December 31, 2025
Acquisitions
Balance as of March 31, 2026
Intangible Asset, Finite-Lived [Table]
Intangible Asset, Finite-Lived [Line Items]
Cost
Accumulated amortization
Net
GoodwillAndIntangiblesNetTable [Table]
Weighted-average amortization period
Amortization of intangible assets
Depreciation and amortization discontinued operations
Remainder of 2026
2027
2028
2029
2030
2031
Thereafter
Total
ScheduleOfInvestmentsInEquityTable [Table]
initial cash investment
Convertible loan
Outstanding equity percentage
Additional contribution
Number of exchange of additional ordinary shares
Equity investment
Value of shares purchased
Share price per unit
Ownership percentage
Long term investments
Schedule of Investments [Table]
Equity method investment
Economic interest
Cost method investment
Total Investments
ScheduleOfGainLossInvestmentsInEquityTable [Table]
Loss from equity method investment
Schedule Of Operating Lease Liability
Remainder of 2026
2027
2028
2029
2030
2031
Thereafter
Total lease payments
Less imputed interest
Total Lease Liabilities
Number of operating leases
Remaining lease term
Operating lease expenses
Operating lease payments
Weighted average remaining lease term
Weighted average discount rate
Short-Term Debt [Table]
Short-Term Debt [Line Items]
Total Debt
Less: unamortized debt issuance costs
Long-term debt
Remainder of 2026
2027
2028
2029
2030
2031
Thereafter
Total debt
Secured term loan
Loans borrowed
Remaining amount available for borrowing
Debt description
Proceeds from loans used for investment
Loans borrowed
Interest rate per annum
Incremental increase during an event of default
Cash paid percentage
Paid-in-kind and aggregate principal loan amount, percentage
Debt upfront fee percentage
Debt instrument back-end fee percentage
Interest paid in cash
Interest paid-in-kind
Interest expense related to back-end fee
Debt instrument rate description
Prepayment of premium due
Minimum cash balance
Annual minimum revenue, year ending December 31, 2024
Annual minimum revenue, year ending December 31, 2025
Annual minimum revenue, year ending December 31, 2026
Annual minimum revenue, year ending December 31, 2027
Annual minimum revenue, January 1, 2028 thereafter
Debt issuance costs
Amortization expense
Loss Contingencies [Table]
Loss Contingencies [Line Items]
Royalty percentage
Royalties paid
Payment for additional royalties
Increase in royalty annual percentage
Sales of royalties recognized
Impairment charge
License Agreement Commitments Description
Royalties percentage
Royalty payments year one
Royalty payments year two
Royalty payments year three
Assets purchase price
Cash consideration paid
Shares issued as consideration
Value of shares issued as consideration
Installment payable
Payment of installment
Purchase agreement description
Number of unique collagen peptides
Outstanding units percentage
Royalty expense percentage
Non-vested shares, beginning
Weighted average grant date fair value, beginning
Granted
Weighted average grant date fair value, granted
Vested
Weighted average grant date fair value, vested
Forfeited
Weighted average grant date fair value, forfeited
Non-vested shares, ending
Weighted average grant date fair value, ending
Options outstanding, beginning
Weighted average exercise price outstanding, beginning
Options, Granted or assumed
Weighted average exercise price, Granted or assumed
Options, Exercised
Weighted average exercise price, Exercised
Options, Forfeited
Weighted average exercise price, Forfeited
Options, Expired
Weighted average exercise price, Expired
Options outstanding, ending
Weighted average exercise price outstanding, ending
Weighted average remaining contract life outstanding
Aggregate intrinsic value, ending
Options exercisable, ending
Weighted average exercise price exercisable, ending
Weighted average remaining contract life exercisable
Aggregate intrinsic value, exercisable
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Maximum number of shares available for grant
Number of shares forfeited
Number of shares granted
Number of shares available for issuance
Stock granted and issued
Shares forfeited
Restricted stock award, gross
Share based compensation excluding discontinued operations
Share-based compensation
Unrecognized share-based compensation expense
Unrecognized share-based compensation expense period for recognition
Related Party Transaction [Table]
Related Party Transaction [Line Items]
Consulting fee
Consulting agreement description
Cost and expenses related party
Net revenue
General and administrative
Sales and marketing
Other expense
Adjusted EBITDA
Interest expense
Noncash share-based compensation
Gain on disposal of property and equipment
Interest income
NonRule 10b51 Arr Modified Flag.
Stock issued during period value for net settlement and retirement of equity based awards.
Stock issued during period shares for net settlement and retirement of equity based awards.
Backend fee.
Accretion of finance liabilities.
Amortization and writeoff of debt issuance costs.
Increase decrease in accounts payable related party.
Increase decrease in accrued royalties and expenses.
Increase decrease in accrued bonuses and commissions.
Cash payment of finance and earnout liabilities.
Nonmonetary exchange to acquire intangible assets.
Conversion of note receivable into equity method investment.
Incremental common shares attributable to nonvested shares.
Unvested Restricted Stock [Member]
Amount of internal use software costs capitalized during the period.
Business combination contingent consideration arrangements change in amount of contingent consideration revaluation of earnout liability.
CRG Term Loan [Member]
Recently Adopted Accounting Pronouncements [Policy Text Block]
Intangible Assets [Member]
Developed Technology [Member]
Class A Preferred Shares [Member]
Pixalere Healthcare Inc. [Member]
Pixalere Healthcare USA LLC [Member]
Precision Healing Merger Agreement [Member]
Accredited Investors [Member]
Warrant One [Member]
Tissue Health Plus [Member]
Disposal group including discontinued operation operating expense abstract
Disposal group including discontinued operation research and development.
Disposal group including discontinued operation other expense abstract.
Disposal group including discontinued operation loss on property and equipment.
CarePICS Acquisition [Member]
Unit Purchase Agreement [Member]
Amount of long-term debt assumed in business combination and recognized at acquisition date, classified as current.
Earnout payment, description.
Earnout payable in cash percentage.
Earnout payable in Purchaser's election percentage.
Earnout payable.
Earnout payable price per patient.
Care PICS [Member]
Business combination cash consideration.
Business combination contingent consideration.
Business combination direct transaction costs.
Customer Relationships and Other [Member]
Amortizable Intangible Assets [Member]
BMI License Agreement [Member]
Outstanding equity percentage.
Additional contribution.
Number of exchange of additional ordinary shares.
Equity investment.
Common Units [Member]
ChemoMouthpiece, LLC [Member]
Direct Dermatology Inc. [Member]
Series B-2 Preferred Shares [Member]
Biomimetic Innovations Limited [Member]
Equity Method Investments Economic Interest.
SI Healthcare Technologies LLC [Member]
Office Space One [Member]
Office Space Two [Member]
CRG Term Loan Agreement [Member]
Gross cash received from the term loan amount.
Cash paid percentage.
Debt instrument upfront fee percentage.
Debt instrument back end fee percentage.
Backend Fee [Member]
Annual minimum revenue year one.
Annual minimum revenue year two.
Annual minimum revenue year three.
Annual minimum revenue year four.
Annual minimum revenue year five.
Royalty percentage.
BIAKOS License Agreement [Member]
Rochal Industries LLC [Member]
BIAKOS Agreement [Member]
ABF License Agreement [Member]
Increase in royalty annual percentage.
License agreement commitments description.
Royalties percentage.
Royalty payments due year one.
Royalty payments due year two.
Royalty payments due year three.
Applied Asset Purchase Agreement [Member]
Cash Closing Consideration [Member]
Stock Closing Consideration [Member]
Purchase agreement description.
Services Agreement [Member]
Number of unique collagen peptides.
License Agreement [Member]
Outstanding units percentage.
Royalty expense percentage.
2024 Omnibus Long-Term Incentive Plan [Member]
2014 Omnibus Long Term Incentive Plan [Member]
Debrider License Agreement [Member]
Consulting Agreement [Member]
Ms Salamone [Member]
Earnings before interest taxes, noncash share-based compensation expense, change in fair value of earnout liabilities, share of losses from equity method investments, executive separation costs, legal and diligence expenses related to acquisitions, asset impairment charges, depreciation and amortization and gains/losses on disposal of property and equipment.
Depreciation of property plant and equipment
Minimum cash balance value.
Total other income (expense)
Share based compensation excluding discontinued operations.
Number of investments.
Share based compensation from discountinued operations.
Contingent consideration liability.
Carrying value of intangible assets.
Share based compensation arrangement by share based payment awards forfeitures in period.
Assets, Current
Assets, Noncurrent
Assets [Default Label]
Liabilities, Current
Liabilities, Noncurrent
Liabilities
Equity, Attributable to Parent
Equity, Including Portion Attributable to Noncontrolling Interest
Liabilities and Equity
Gross Profit
Operating Expenses
Operating Income (Loss)
Other Nonoperating Income (Expense)
Income (Loss) from Continuing Operations, Per Diluted Share
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share
Shares, Outstanding
Depreciation, Depletion and Amortization
Asset, Impairment Loss
Share-Based Payment Arrangement, Noncash Expense
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Accounts Receivable, Related Parties
Increase (Decrease) in Inventories
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Accounts Payable
IncreaseDecreaseInAccruedRoyaltiesAndExpenses
IncreaseDecreaseInAccruedBonusesAndCommissions
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Payments to Acquire Property, Plant, and Equipment
Payments to Acquire Equity Method Investments
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
CashPaymentOfFinanceAndEarnoutLiabilities
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]
Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization
Business Combination, Contingent Consideration, Liability
Debt Issuance Costs, Net
Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net
Disposal Group, Including Discontinued Operation, Other Liabilities, Current
Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current
DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment
Disposal Group, Including Discontinued Operation, Depreciation and Amortization
Depreciation [Default Label]
BusinessCombinationCashConsideration
Business Combination, Consideration Transferred
Business Combination, Recognized Liability Assumed, Long-Term Debt, Current
Intangible Asset, Finite-Lived, after Accumulated Amortization
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year
Lessee, Operating Lease, Liability, to be Paid, Year One
Lessee, Operating Lease, Liability, to be Paid, Year Two
Lessee, Operating Lease, Liability, to be Paid, Year Three
Lessee, Operating Lease, Liability, to be Paid, Year Four
Lessee, Operating Lease, Liability, to be Paid, Year Five
Lessee, Operating Lease, Liability, to be Paid, after Year Five
Lessee, Operating Lease, Liability, to be Paid
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Long-Term Debt
Long-Term Debt, Maturity, Remainder of Fiscal Year
Long-Term Debt, Maturity, Year One
Long-Term Debt, Maturity, Year Two
Long-Term Debt, Maturity, Year Three
Long-Term Debt, Maturity, Year Four
Long-Term Debt, Maturity, Year Five
Long-Term Debt, Maturity, after Year Five
Short-Term Debt
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
ShareBasedCompensationFromDiscountinuedOperations